Genomics software company Biomatters has appointed former managing director Dr Brett
Ammundsen as chief executive to lead the
company as genomics progresses from research into new clinical and consumer
With a career in science and several peer-reviewed publications and patents to his name, Ammundsen sees an important role for providers of bioinformatics tools ahead.
“There is a lot of excitement about the
$1000 genome, but sequencing entire genomes at a low cost generates an enormous
amount of data which requires expert interpretation. To truly realise the
promise of genomics, we need smart interfaces allowing clinicians and consumers
to connect to the knowledge associated with the genomic data, and make real
world decisions with confidence."
Ammundsen is a strong supporter of the vision of
personal genomics and is participating in the 23andMe pilot exome project.
“There is nothing quite like looking at your own genomic data,” he said. “It’s an insight into the lineage of your past as well as your potential future."
Biomatters chairman Greg Casagrande said Ammundsen was seasoned in the commercialisation of leading-edge science.
“The appointment of Brett comes at a time when the genomics industry and our customers are experiencing a game-changing revolution in both genome sequencing and computing technologies."